BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35439353)

  • 21. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM; Ekberg H; Mamelok RD; Oppenheimer F; Sánchez-Plumed J; Gentil MA; Hernandez D; Kuypers DR; Brunet M
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion From Cyclosporine to Once-Daily Tacrolimus on 50:1 mg Basis: A Short-Term Pilot Study.
    Shimada H; Uchida J; Kosoku A; Iwai T; Kabei K; Nishide S; Naganuma T; Kumada N; Takemoto Y; Nakatani T
    Exp Clin Transplant; 2020 Feb; 18(1):1-7. PubMed ID: 31180299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.
    Sansone-Parsons A; Krishna G; Martinho M; Kantesaria B; Gelone S; Mant TG
    Pharmacotherapy; 2007 Jun; 27(6):825-34. PubMed ID: 17542765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels.
    Scheibner AC; Franco-Martinez C; Kincaide E; Hall R; Long C
    Prog Transplant; 2021 Sep; 31(3):236-241. PubMed ID: 34155947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcineurin Inhibitor-Based Maintenance Immunosuppression in Lung Transplant Recipients: Optimal Serum Levels for Managing Acute Rejection and Renal Function.
    McPheeters CM; Lorenz D; Burcham PK; Barger CD; Bhandari B; Bauldoff GS; Truelove DB; Nunley DR
    Transplant Proc; 2021; 53(6):1998-2003. PubMed ID: 34253383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
    Božina N; Lalić Z; Nađ-Škegro S; Borić-Bilušić A; Božina T; Kaštelan Ž; Trkulja V
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients.
    Jones TE; Morris RG
    Clin Pharmacokinet; 2002; 41(5):381-8. PubMed ID: 12036394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects.
    Bifano M; Adamczyk R; Hwang C; Kandoussi H; Marion A; Bertz RJ
    Clin Drug Investig; 2015 May; 35(5):281-9. PubMed ID: 25896946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome.
    Han Y; Du SQ; Xiao HJ; Zhou Y; Ding J; Ding JJ; Cui YM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):807-813. PubMed ID: 29045960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
    van Gelder T
    Kidney Int; 2021 Dec; 100(6):1185-1189. PubMed ID: 34284043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of minimum whole-blood tacrolimus concentration for therapeutic drug monitoring with plasma prednisolone concentration: A retrospective cohort study in Japanese kidney transplant recipients.
    Sugioka N; Matsushita A; Kokuhu T; Bpharm ; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
    Curr Ther Res Clin Exp; 2006 Mar; 67(2):103-17. PubMed ID: 24678088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.
    Schachter AD; Benfield MR; Wyatt RJ; Grimm PC; Fennell RS; Herrin JT; Lirenman DS; McDonald RA; Munoz-Arizpe R; Harmon WE
    Pediatr Transplant; 2006 Dec; 10(8):914-9. PubMed ID: 17096757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study.
    Garonzik S; Byon W; Myers E; Li X; Marchisin D; Murthy B
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):561-567. PubMed ID: 31030414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.